Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a significant stock price increase, rising over 7% and currently trading at 9.59 HKD, with a trading volume of 32.19 million HKD. The company is set to hold a board meeting on August 28 to approve its mid-term performance, with expectations of a profit of no less than 20 million RMB for the first half of the year, compared to a loss of approximately 44.90 million RMB in the same period last year. The turnaround is attributed to milestone revenues from three authorized collaborations and sales from commercialized products. Additionally, the company has received acceptance for its clinical trial application for the dual-specific antibody-drug conjugate JSKN022, aimed at treating advanced malignant solid tumors, marking a significant development in the market as no similar targeted ADCs are currently available globally [1][1][1]. Financial Performance - The company anticipates a profit of at least 20 million RMB for the first half of the year, a notable recovery from a loss of around 44.90 million RMB in the previous year [1][1][1]. - The financial turnaround is primarily driven by milestone revenues from three authorized collaborations and sales from commercialized products [1][1][1]. Product Development - Corning Jereh Pharmaceutical has announced that its self-developed dual-specific antibody-drug conjugate JSKN022 has had its clinical trial application formally accepted by the National Medical Products Administration of China [1][1][1]. - The planned clinical study for JSKN022 will focus on treating advanced malignant solid tumors, with no existing targeted ADCs for integrin αvβ6 or PD-L1 currently available on the market [1][1][1].
港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩 预计上半年利润不少于2000万元